Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
939.90B
Market cap939.90B
Price-Earnings ratio
43.15
Price-Earnings ratio43.15
Dividend yield
0.63%
Dividend yield0.63%
Average volume
3.14M
Average volume3.14M
High today
$1,005.86
High today$1,005.86
Low today
$977.00
Low today$977.00
Open price
$987.39
Open price$987.39
Volume
1.28M
Volume1.28M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

The current Eli Lilly(LLY) stock price is $996.60, with a market capitalization of 939.9B. The stock trades at a price-to-earnings (P/E) ratio of 43.15 and offers a dividend yield of 62.9%.

As of 2026-03-09, Eli Lilly(LLY) stock has fluctuated between $977.00 and $1,005.86. The current price stands at $996.60, placing the stock +2.0% above today's low and -0.9% off the high.

Eli Lilly(LLY) shares are trading with a volume of 1.28M, against a daily average of 3.14M.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.

LLY News

Investor's Business Daily 2h
Roche Tumbles, Taking Olema With It, On A High-Profile Failure

How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity 1/29/2026 Roche hopes to rival Eli Lilly and Novo Nordisk in the red-hot weight-loss s...

Roche Tumbles, Taking Olema With It, On A High-Profile Failure
TipRanks 6h
Amazon Pharmacy expands access to Eli Lilly Zepbound KwikPen

Amazon Pharmacy (AMZN) announced expanded access to the new Zepbound KwikPen through Amazon Pharmacy. Eli Lilly’s (LLY) multi-dose injectable treatment for weig...

Simply Wall St 1d
Eli Lilly Employer Connect Launch Puts Obesity Drug Push And Rich Valuation Under The Microscope

Eli Lilly (LLY) is in focus after launching its Employer Connect platform for Zepbound, giving U.S. employers new ways to structure obesity drug coverage and wo...

Eli Lilly Employer Connect Launch Puts Obesity Drug Push And Rich Valuation Under The Microscope

Analyst ratings

80%

of 35 ratings
Buy
80%
Hold
17.1%
Sell
2.9%

More LLY News

Nasdaq 2d
Where Will Eli Lilly Stock Be in 10 Years?

Key Points Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known...

Where Will Eli Lilly Stock Be in 10 Years?
The Motley Fool 3d
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?

Is Novo Nordisk (NVO 1.27%) a bargain or a value trap as it battles Eli Lilly (LLY +0.70%) for GLP‑1 leadership, execution credibility, and premium growth? Watc...

Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
TipRanks 4d
Eli Lilly’s Abemaciclib Combo Pushes Deeper Into Advanced Prostate Cancer

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 1b study “A Phase 1b Study of Abemaciclib Plus Darolutamide in Men W...

TipRanks 4d
Your Boss May Soon Cover the Cost of Obesity Drugs. Here’s Eli Lilly’s Plan

U.S. pharmaceutical giant Eli Lilly (LLY) has launched a new program designed to help more employers cover the cost of weight-loss medications. Currently, a la...

Nasdaq 4d
Lilly Launches Employer Connect Platform To Expand Access To Obesity Treatments

(RTTNews) - Eli Lilly and Company (LLY) on Thursday announced the launch of its Employer Connect platform, aimed at expanding access to obesity management treat...

Lilly Launches Employer Connect Platform To Expand Access To Obesity Treatments
Benzinga 4d
Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform

Eli Lilly and Company (NYSE:LLY) rolled out its new Employer Connect platform on Wednesday, targeting the roughly half of commercially insured American employee...

Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform
Simply Wall St 4d
Eli Lilly’s Nvidia AI Deal And Pipeline Progress Versus Rich Valuation

Eli Lilly (NYSE:LLY) has entered a $1 billion AI-focused drug discovery partnership with Nvidia, aimed at using advanced computing to support pharmaceutical R&D...

Eli Lilly’s Nvidia AI Deal And Pipeline Progress Versus Rich Valuation

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.